Ebastine inhibits T cell migration, production of Th2-type cytokines and proinflammatory cytokines

Clinical and Experimental Allergy

Volumn 33, Issue 11, 2003, Pages 1544-1554

  Nori, M ^a   Iwata, S ^a   Munakata, Y ^b   Kobayashi, H ^a   Kobayashi, S ^a   Umezawa, Y ^c   Hosono, O ^a   Kawasaki, H ^a   Dang, N H ^d   Tanaka, H ^a   Shiohara, T ^e   Morimoto, C ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e KYORIN UNIVERSITY   (Japan)

Author keywords

CD26; CD28; CD3; Ebastine; IL 4; IL 5; IL 6; T cell co stimulation; T cell migration; TNF

Indexed keywords

CYTOKINE; EBASTINE; GAMMA INTERFERON; HISTAMINE H1 RECEPTOR ANTAGONIST; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; THYMIDINE; TUMOR NECROSIS FACTOR ALPHA;

ALLERGIC REACTION; ARTICLE; CELL MIGRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; MACROPHAGE; PRIORITY JOURNAL; T LYMPHOCYTE;

ANTIGENS, CD; BUTYROPHENONES; CELL DIVISION; CELL MOVEMENT; CELLS, CULTURED; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; ENDOTHELIUM; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; KETOTIFEN; LYMPHOCYTE ACTIVATION; MACROPHAGES; PIPERIDINES; T-LYMPHOCYTE SUBSETS; TH1 CELLS; TH2 CELLS;

EID: 10744223108     PISSN: 09547894     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2222.2003.01701.x     Document Type: Article

References (47)

1. Storms WW. Clinical studies of the efficacy and tolerability of ebastine 10 or 20 mg once daily in the treatment of seasonal allergic rhinitis in the US. Drugs 1996; 52(Suppl 1):20-5.
2. Kalis B. Double-blind multicentre comparative study of ebastine, terfenadine and placebo in the treatment of chronic idiopathic urticaria in adults. Drugs 1996; 52(Suppl 1):30-4.
3. Ohtani H, Sato H, Iga T, Kotaki H, Sawada Y. Pharmacokinetic- pharmacodynamic analysis of the arrhythmogenic potency of a novel antiallergic agent, ebastine, in rats. Biopharm Drug Dispos 1999; 20:101-6.
4. Gillen MS, Miller B, Chaikin P, Morganroth J. Effects of supratherapeutic doses of ebastine and terfenadine on the QT interval. Br J Clin Pharmacol 2001; 52:201-4.
5. Roberts DJ. Assessing the cardiac safety of ebastine. Epilogue. Drug Saf 1999; 21(Suppl 1):89-92.
6. Roberts DJ. A preclinical overview of ebastine. Studies on the pharmacological properties of a novel histamine H1 receptor antagonist. Drugs 1996; 52(Suppl 1):8-14.
7. Massey WA, Lichtenstein LM. The effects of antihistamines beyond H1 antagonism in allergic inflammation. J Allergy Clin Immunol 1990; 86:1019-24.
8. Crampette L, Mainprice B, Bloom M, Bousquet J, Campbell AM. Inhibition of mediator and cytokine release from dispersed nasal polyp cells by terfenadine. Allergy 1996; 51:346-9.
9. Kapsenberg ML, Wierenga EA, Bos JD, Jansen HM. Functional subsets of allergen-reactive human CD4+ T cells. Immunol Today 1991; 12:392-5.
10. Romagnani S. Lymphokine production by human T cells in disease states. Annu Rev Immunol 1994; 12:227-57.
11. Del Prete GF, De Carli M, D'Elios MM et al. Allergen exposure induces the activation of allergen-specific Th2 cells in the airway mucosa of patients with allergic respiratory disorders. Eur J Immunol 1993; 23:1445-9.
12. + T cells, increased TH2-type cytokine mRNA expression, and eosinophil recruitment in bronchoalveolar lavage after allergen inhalation challenge in patients with atopic asthma. J Allergy Clin Immunol 1993; 92:313-24.
13. Maggi E, Biswas P, Del Prete G et al. Accumulation of Th-2-like helper T cells in the conjunctiva of patients with vernal conjunctivitis. J Immunol 1991; 146:1169-74.
14. Robey E, Allison JP. T-cell activation: integration of signals from the antigen receptor and costimulatory molecules. Immunol Today 1995; 16:306-10.
15. Green JM, Noel PJ, Sperling AI et al. Absence of B7-dependent responses in CD28-deficient mice. Immunity 1994; 1:501-8.
16. Gimmi CD, Freeman GJ, Gribben JG et al. B-cell surface antigen B7 provides a costimulatory signal that induces T cells to proliferate and secrete interleukin 2. Proc Natl Acad Sci USA 1991; 88:6575-9.
17. Freeman GJ, Borriello F, Hodes RJ et al. Uncovering of functional alternative CTLA-4 counter-receptor in B7-deficient mice. Science 1993; 262:907-9.
18. Linsley PS, Ledbetter JA. The role of the CD28 receptor during T cell responses to antigen. Annu Rev Immunol 1993; 11:191-212.
19. Morimoto C, Torimoto Y, Levinson G et al. 1F7, a novel cell surface molecule, involved in helper function of CD4 cells. J Immunol 1989; 143:3430-9.
20. Dang NH, Torimoto Y, Deusch K, Schlossman SF, Morimoto C. Comitogenic effect of solid-phase immobilized anti-1F7 on human CD4 T cell activation via CD3 and CD2 pathways. J Immunol 1990; 144:4092-100.
21. Tanaka T, Kameoka J, Yaron A, Schlossman SF, Morimoto C. The costimulatory activity of the CD26 antigen requires dipeptidyl peptidase IV enzymatic activity. Proc Natl Acad Sci USA 1993; 90:4586-90.
22. Hafler DA, Fox DA, Manning ME, Schlossman SF, Reinherz EL, Weiner HL. In vivo activated T lymphocytes in the peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. N Engl J Med 1985; 312:1405-11.
23. Nakao H, Eguchi K, Kawakami A et al. Increment of Tl1 positive cells in peripheral blood from patients with rheumatoid arthritis. J Rheumatol 1989; 16:904-10.
24. Iwata S, Yamaguchi N, Munakata Y et al. CD26/dipeptidyl peptidase IV differentially regulates the chemotaxis of T cells and monocytes toward RANTES: possible mechanism for the switch from innate to acquired immune response. Int Immunol 1999; 11:417-26.
25. Johnston RB Jr. Current concepts: immunology. Monocytes and macrophages. N Engl J Med 1988; 318:747-52.
26. Matsuda M, Sakashita M, Mizuki Y, Yamaguchi T, Fujii T, Sekine Y. Comparative pharmacokinetics of the histamine H1-receptor antagonist ebastine and its active metabolite carebastine in rats, guinea pigs, dogs and monkeys. Arzneimittelforschung 1994; 44:55-9.
27. Rimmer SJ, Church MK. The pharmacology and mechanisms of action of histamine H1-antagonists. Clin Exp Allergy 1990; 20(Suppl 2):3-17.
28. Buendia E. Ebastine in context. Introduction. Drugs 1996; 52(Suppl 1):1-7.
29. Campbell A, Michel FB, Bremard-Oury C, Crampette L, Bousquet J. Overview of allergic mechanisms. Ebastine has more than an antihistamine effect. Drugs 1996; 52(Suppl 1):15-9.
30. Jutel M, Watanabe T, Klunker S et al. Histamine regulates T-cell and antibody responses by differential expression of H1 and H2 receptors. Nature 2001; 413:420-5.
31. Butcher EC, Picker LJ. Lymphocyte homing and homeostasis. Science 1996; 272:60-6.
32. Robinson DS, Hamid Q, Ying S et al. Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med 1992; 326:298-304.
33. + T cells, eosinophils, and mast cells in bronchial biopsies obtained from atopic and nonatopic (intrinsic) asthmatics. J Immunol 1997; 158:3539-44.
34. Munakata Y, Umezawa Y, Iwata S et al. Specific inhibition of TH2-type cytokine production from human peripheral T cells by terfenadine in vitro. Clin Exp Allergy 1999; 29: 1281-6.
35. Woosley RL. Cardiac actions of antihistamines. Annu Rev Pharmacol Toxicol 1996; 36:233-52.
36. Negro-Alvarez JM, Funes E, Garcia Canovas A et al. Antiallergic properties of antihistamines. Allergol Immunopathol (Madr) 1996; 24:177-83.
37. Masuyama J, Berman JS, Cruikshank WW, Morimoto C, Center DM. Evidence for recent as well as long term activation of T cells migrating through endothelial cell monolayers in vitro. J Immunol 1992; 148:1367-74.
38. Ohashi Y, Iwata S, Kamiguchi K, Morimoto C. Tyrosine phosphorylation of Crk-associated substrate lymphocyte-type is a critical element in TCR-and beta 1 integrin-induced T lymphocyte migration. J Immunol 1999; 163:3727-34.
39. Liu Y, Merlin D, Burst SL, Pochet M, Madara JL, Parkos CA. The role of CD47 in neutrophil transmigration. Increased rate of migration correlates with increased cell surface expression of CD47. J Biol Chem 2001; 276:40156-66.
40. Gibbs BF, Vollrath IB, Albrecht C, Amon U, Wolff HH. Inhibition of interleukin-4 and interleukin-13 release from immunologically activated human basophils due to the actions of anti-allergic drugs. Naunyn Schmiedebergs Arch Pharmacol 1998; 357:573-8.
41. Nathan CF. Secretory products of macrophages. J Clin Invest 1987; 79:319-26.
42. Marone G, Gentile M, Petraroli A, De Rosa N, Triggiani M. Histamine-induced activation of human lung macrophages. Int Arch Allergy Immunol 2001; 124:249-52.
43. Amrani Y, Chen H, Panettieri RA Jr. Activation of tumor necrosis factor receptor 1 in airway smooth muscle: a potential pathway that modulates bronchial hyper-responsiveness in asthma? Respir Res 2000; 1:49-53.
44. Hirano T. Interleukin 6 and its receptor: ten years later. Int Rev Immunol 1998; 16:249-84.
45. Virchow JC Jr., Walker C, Hafner D et al. T cells and cytokines in bronchoalveolar lavage fluid after segmental allergen provocation in atopic asthma. Am J Respir Crit Care Med 1995; 151:960-8.
46. Taylor PC, Williams RO, Maini RN. Immunotherapy for rheumatoid arthritis. Curr Opin Immunol 2001; 13:611-6.
47. Kam LY, Targan SR. TNF-alpha antagonists for the treatment of Crohn's disease. Expert Opin Pharmacother 2000; 1:615-22.